Inovio COVID-19 vaccine data highlight questions about antibody versus T cell responses

A chilly market reception for Inovio’s Phase I COVID-19 vaccine data suggests antibody titers are the key benchmark investors are looking for. The move raises questions about how to value vaccines when the correlates of protection are still unclear.

On Tuesday, Inovio Pharmaceuticals Inc. (NASDAQ:INO) announced 34 out of 36 (94%) trial participants showed “overall immune responses” at week six following two doses of INO-4800, a DNA vaccine encoding the SARS-CoV-2 spike protein. ...